In silico– tag –
-
Isomorphic Labs’ AlphaFold 3-Designed AI Drug Candidates Enter First-in-Human Clinical Trials for Solid Tumors
IntuitionLabs USA Overview Isomorphic Labs, a Google DeepMind spin-off, has initiated first-in-human clinical trials for oncology candidates designed using AlphaFold 3 and proprietary AI models. This landmark achievement signifies one of... -
Challenges in AI Drug Discovery Clinical Success Rates: Insilico’s Lenticelib First to Phase II, AlphaFold Accelerates Structural Biology
MDPI Switzerland Overview While AI drug discovery accelerates early-stage discovery, consistent improvement in late-stage clinical trial success rates remains a challenge. However, Insilico Medicine's lenticelib (NCT05938920) has become ... -
AI-Designed Drugs from DeepMind’s AlphaFold, Insilico, and Generate Biomedicines Advance to Mid-Late Stage Clinical Trials, Intensifying Drug Discovery Race
MedCity News USA Overview The AI drug discovery sector is intensifying as advanced AI-designed drugs are poised to deliver mid-to-late stage clinical trial results within the next two years, leveraging breakthroughs like DeepMind's Alpha... -
Isomorphic Labs Secures $2.1B Series B Funding to Scale AI Drug Discovery Platform ‘IsoDDE’
IntuitionLabs UK Overview Isomorphic Labs, a Google DeepMind spin-off, has successfully raised $2.1 billion in Series B funding to globally expand its AI-driven drug discovery platform, 'IsoDDE,' and advance multiple drug programs. Built... -
AI Propels Drug Discovery with Breakthroughs in Protein Structure Prediction and Generative Molecular Design
AI Medicine Today USA Overview Artificial intelligence is dramatically accelerating drug discovery across multiple stages, from target identification to clinical trial optimization. DeepMind's AlphaFold has revolutionized protein structu... -
Reliability of AI Antibody Design Hinges on Training Data: AlphaFold Era Highlights Data Quality Challenge
Drug Discovery News USA Overview Advancements in protein AI, such as AlphaFold, have ushered in a new computational era for antibody discovery, enabling predictions of protein folding and interactions with near-experimental accuracy. How... -
Imperial College London’s DeCAF-Pearl AI Model Enables Practical Large-Scale Molecular Screening, Surpassing AlphaFold 3 Efficiency
Imperial College London UK Overview Researchers at Imperial College London, in collaboration with the Genesis Research Team, have developed DeCAF-Pearl, a new AI model based on flow maps that makes large-scale molecular screening practic... -
UVA’s YuelDesign AI Framework Models Protein Flexibility for Improved Drug Design, Demonstrating Success on CDK2 Target
IntuitionLabs USA Overview The YuelDesign framework, developed by a UVA team, represents a significant advancement in structure-based drug design by explicitly modeling protein flexibility during ligand generation using AI diffusion mode... -
Isomorphic Labs Advances AI-Designed Oncology and Immunology Therapeutics to Clinical Trials Leveraging AlphaFold 3
IntuitionLabs UK Overview Isomorphic Labs is advancing its first computationally designed oncology and immunology therapeutics into clinical trials, leveraging AlphaFold-derived AI models, including AlphaFold 3. The company aims to drast... -
Protai Introduces Structural-Proteomics-Guided AI ‘AIMS-Fold’ to Revolutionize Induced Proximity Drug Design
BioSpace USA Overview Protai announced two preprints introducing AIMS-Fold, a structural-proteomics-guided generative AI framework for protein complex modeling, specifically for induced proximity therapeutics like PROTACs and molecular g...
